title: Evolving synergistic combinations of targeted immunotherapies to combat cancer.
abstract: Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of immunotherapy agents and for combining immunotherapy agents with conventional cancer treatments. Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future approaches to immuno-oncology combination therapy. In this Review, we discuss progress in the synergistic design of immune-targeting combination therapies and highlight the challenges involved in tailoring such strategies to provide maximal benefit to patients.
authors.affiliation: Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Melero
authors.affiliation: Bristol-Myers Squibb, 3551 Lawrenceville Princeton, New Jersey 08648, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Berman
authors.affiliation: Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
authors.forename: M Angela
authors.initials: MA
authors.lastname: Aznar
authors.affiliation: Bristol-Myers Squibb Biologics Discovery California, 700 Bay Road, Redwood City, California 94063, USA.
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Korman
authors.affiliation: Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Pérez Gracia
authors.affiliation: The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
authors.forename: John
authors.initials: J
authors.lastname: Haanen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D059016:Tumor Microenvironment / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor